Pamela McShane, MD
Pulmonary Disease · Tyler, TXNPI 1093791808
Payments from drug & device makers
Across 895 payments — averaging $1520.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$770K
- Insmed, Inc.$395K
- Boehringer Ingelheim International GmbH$60K
- Mannkind Corporation$36K
- Boehringer Ingelheim Pharma GmbH & Co.kg$30K
- AstraZeneca$28K
- plus $42K from 24 others
Across 7 payments — averaging $104.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$734
What the payments were for
- Consulting fees$103,41356%
- Speaking & faculty fees$63,55435%
- Travel & lodging$11,5476%
- Food & beverage$5,3223%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 26 | $769,824 |
| Insmed, Inc. | 690 | $394,697 |
| Boehringer Ingelheim International GmbH | 62 | $60,475 |
| Mannkind Corporation | 3 | $36,000 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $30,122 |
| AstraZeneca | 13 | $28,109 |
| Sanofi US Services Inc. | 1 | $21,634 |
| Paratek Pharmaceuticals, Inc. | 3 | $13,717 |
| Redhill Biopharma Inc. | 3 | $5,250 |
| GSK | 40 | $471 |
| United Therapeutics Corporation | 7 | $137 |
| Harmony Biosciences LLC | 8 | $134 |
| Sanofi | 6 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Mylan Specialty L.p. | 4 | $54 |
| Grifols USA, LLC | 3 | $53 |
| Genentech USA, Inc. | 3 | $47 |
| Baxter Healthcare | 2 | $42 |
| Electromed, Inc. | 3 | $34 |
| Merck | 2 | $31 |
| Amgen | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Hospira, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,361,177 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 101 | $1,476,064 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $116,975 |
| NuzyraOmadacycline Tosylate | 12 | $107,260 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $91,607 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 145 | $72,163 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 96 | $59,985 |
| Tigecycline | 94 | $27,815 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 123 | $26,865 |
| Ethambutol Hcl | 380 | $18,257 |
| Azithromycin | 437 | $11,663 |
| TygacilTigecycline | 20 | $11,517 |
| Gentamicin Sulfate | 81 | $10,845 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $10,767 |
| Rifabutin | 22 | $9,675 |
| Amikacin Sulfate | 130 | $9,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $394,697 | $1,476,064101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $471 | $182,452312 claims |
| Grifols USA, LLCProlastin C | $53 | $116,97513 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $13,717 | $107,26012 claims |
| Boehringer IngelheimStiolto Respimat | $769,824 | $59,98596 claims |
| PfizerTygacil | $17 | $11,51720 claims |
| AstraZenecaBevespi Aerosphere | $28,109 | $5,53814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Tyler
- Julie PhilleyTyler$2.4M
- Megan DevineTyler$309K
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.